MyelofibrosisGraft-versus-HydroxyureaErythrocytosisPatientsRuxolitinibEssentialPhlebotomySplenomegalyTreatmentFindingsLiverInitialYearTreatEventsApproval2016Macroglobulinemia2019ErythrocytosisThromboembolismSecondary2021ThrombocythaemiaDiagnosisComplicationsChronicSplenectomyPlatelet countMolecularClinicalAcuteVenousTherapeuticPublicationSearchBlood
Myelofibrosis8
- MPD includes polycythemia vera (PV), essential thrombocytopenia (ET), and primary myelofibrosis (PMF). (medicarepaymentandreimbursement.com)
- Patient would meet World Health Organization's diagnostic criteria for myeloproliferative disease (i.e. polycythemia vera, essential thrombocytopenia, primary myelofibrosis) if JAK2 V617F were identified. (medicarepaymentandreimbursement.com)
- In the United States and the European Union, ruxolitinib is indicated for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia-vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. (wikipedia.org)
- [ 5 ] Primary myelofibrosis is categorized as a chronic myeloproliferative disorder, along with chronic myelogenous leukemia (CML), polycythemia vera , and essential thrombocytosis . (medscape.com)
- Total patients grew across myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD). (businesswire.com)
- Ruxolitinib was the first drug approved (2011) to specifically treat patients with the intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis. (org.in)
- The most common (classic) MPNs are chronic myeloid leukemia ( CML ), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). (amboss.com)
- Imago's lead candidate, bomedemstat, an investigational orally available lysine-specific demethylase 1 inhibitor, is currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis and polycythemia vera, in addition to other indications. (roi-nj.com)
Graft-versus-2
- In May 2019, the indication for ruxolitinib was expanded in the US to include steroid-refractory acute graft-versus-host disease. (wikipedia.org)
- The indication was further expanded in the US in September 2021, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in people 12 years of age and older. (wikipedia.org)
Hydroxyurea9
- It is also indicated for the treatment of adults with polycythaemia vera who are resistant to or intolerant of hydroxyurea. (wikipedia.org)
- In 2014, it was approved in polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea, based on the RESPONSE trial. (wikipedia.org)
- Appropriately, they begin on cytoreductive therapy, and that hydroxyurea is indicated for individuals who are tolerating phlebotomy as the sole management of polycythemia vera. (targetedonc.com)
- This individual continues on hydroxyurea based on the need for continued phlebotomies, and now he develops progressive pruritus, a common symptom of polycythemia vera. (targetedonc.com)
- In many ways, this individual now meets the criteria established by the European LeukemiaNet that defines hydroxyurea resistance for an individual with polycythemia vera. (targetedonc.com)
- Sever M, Newberry KJ, Verstovsek S. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. (jakavi.com)
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. (jakavi.com)
- Ruxolitinib was approved by FDA (2014) to treat polycythemia vera patients who have an inadequate response to or cannot tolerate hydroxyurea. (org.in)
- This was a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea. (org.in)
Erythrocytosis2
- For the individual in which phlebotomy works well, we typically see that the need for a number of phlebotomies goes down relatively rapidly and that we are inducing an iatrogenic state of iron deficiency to try to control the erythrocytosis that individuals have with polycythemia vera. (targetedonc.com)
- 12. Ruggeri M., Tosetto A., Frezzato M., Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis // Ann. (medline.ru)
Patients10
- Last year started off with the expanded indication for lenalidomide maintenance therapy in patients with multiple myeloma, following autologous stem cell transplant. (gotoper.com)
- Winter concluded with further approvals of pembrolizumab in classical Hodgkin lymphoma following three or more lines of therapy and a diagnostic PCR for JAK2 mutations for patients with polycythemia vera. (gotoper.com)
- Food and Drug Administration expanded the indication of pomalidomide (POMALYST, Celgene Corporation) to include treating adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative. (blogspot.com)
- The long-term risks of polycythemia vera (PV) include leukemic and fibrotic transformation, which occur in fewer than 5% and 10% of patients, respectively, at 10 years. (medscape.com)
- Should this decision be made final within the Final Appraisal Determination (FAD) expected in January 2017, it would mean that patients in England would be denied access to a medicine that has transformed treatment paradigms and given many patients the opportunity to achieve a potential cure with or without a stem cell transplant. (hospitalhealthcare.com)
- Brentuximab vedotin is being reviewed by NICE for the initial launch indications and also for a new indication, granted marketing authorisation by the European Commission in June 2016, for the treatment of patients with CD30+ HL at increased risk of relapse or progression following ASCT. (hospitalhealthcare.com)
- Dr. Jay Mei, Founder, Chairman and CEO of Antengene , commented: "The NMPA's approval for this clinical trial of selinexor in patients with MF marks another major milestone in our effort in developing selinexor in a broad range of diseases, and a big step towards expanding potential indications for this candidate drug. (antengene.com)
- RESPONSE-2 assessed the efficacy and safety of ruxolitinib in controlling disease in patients with polycythaemia vera without splenomegaly (no palpable spleen at enrollment) who need second-line therapy. (org.in)
- Since the beginning of 2017 almost all patients treated with imatinib are treated with one of the generic drugs available. (fcarreras.org)
- Although AML is the most common indication for allogeneic HCT, the relatively small number of patients and the highly complex nature of the procedure often render prospective studies on HCT unfeasible. (apbmt.org)
Ruxolitinib2
- In this RESPONSE trial it was shown that ruxolitinib was superior to standard therapy in controlling the hematocrit, reducing the spleen volume, and improving symptoms associated with polycythemia vera and hence it was approved for this indication. (org.in)
- Ruxolitinib is the first and only FDA-approved treatment for this indication. (org.in)
Essential1
- MF is a clonal bone narrow neoplasm which can emerge either as primary MF (PMF), polycythemia vera (PV) or essential thrombocythemia (ET). (antengene.com)
Phlebotomy3
- A continued need for phlebotomy well into the management of polycythemia vera can be problematic on a variety of levels. (targetedonc.com)
- Aetna considers therapeutic phlebotomy experimental and investigational for treatment of the following conditions because its effectiveness for these indications has not been established (not an all-inclusive list). (aetna.com)
- Therapeutic phlebotomy may be indicated for hemochromatosis, polycythemia vera, porphyria cutanea tarda, and polycythemia secondary to arterio-venous fistulae, cyanotic congenital heart disease or cor pulmonale. (aetna.com)
Splenomegaly1
- Refractory splenomegaly may be an indication for splenectomy. (medscape.com)
Treatment2
- The current review enlightens the pathogenesis of the disease, clinical indications, diagnostic evaluation, and various therapies for the treatment. (ijpsr.com)
- and SLN124 for the treatment of polycythemia vera. (financialmodelingprep.com)
Findings1
- The optimal management remains elusive despite the findings of the Polycythemia Vera Study Group (PVSG). (medscape.com)
Liver1
- In polycythaemia vera, the most common side effects include anemia (low red blood cell counts) and thrombocytopenia (low blood platelet count), bleeding, bruising, hypercholesterolaemia (high blood cholesterol levels), hypertriglyceridemia (high blood fat levels), dizziness, raised liver enzyme levels and high blood pressure. (wikipedia.org)
Initial1
- 3 It would also introduce an inequality of care across the UK, as access to the initial indications for brentuximab vedotin was granted by the Scottish Medicines Consortium and the All Wales Medicine Strategy Group in 2014 and 2015, respectively. (hospitalhealthcare.com)
Year2
- 2017 was the year to be a hematologist. (gotoper.com)
- Our first quarter results demonstrate continued year-over-year double-digit revenue growth driven by Jakafi, which grew across all indications, and Opzelura, which is on track to become one of the most successful dermatology launches in recent years. (businesswire.com)
Treat1
- Are you prepared to treat your next polycythaemia vera patient? (jakavi.com)
Events1
- Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. (jakavi.com)
Approval1
- July brought us the regular approval of blinatumomab for ALL as well as an expanded indication. (gotoper.com)
20161
- Brentuximab vedotin is being reviewed by NICE for the initial launch indications and also for a new indication, granted marketing authorisation by the European Commission in June 2016, for the treatment of patients with CD30+ HL at increased risk of relapse or progression following ASCT. (hospitalhealthcare.com)
Macroglobulinemia1
- Chlorambucil has also been used for macroglobulinemia, polycythemia vera, rheumatoid arthritis, autoimmune uveitis and minimal change nephrotic syndrome, but its link to development of leukemia and secondary cancers has led to recommendations that its use be restricted to malignant conditions. (nih.gov)
20191
- In May 2019, the indication for ruxolitinib was expanded in the US to include steroid-refractory acute graft-versus-host disease. (wikipedia.org)
Erythrocytosis2
- Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. (medscape.com)
- Polycythemia vera is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis). (cancerhealth.com)
Thromboembolism1
- Prevalence of venous thromboembolism in patients with secondary polycythemia. (medscape.com)
Secondary6
- Correction of the underlying cause of secondary polycythemia is the most important element of managment. (medscape.com)
- Some patients with extreme secondary polycythemia have impaired alertness, dizziness, headaches, and compromised exercise tolerance. (medscape.com)
- Some cases of secondary polycythemia are caused by conditions that can be ameliorated by surgical removal or correction. (medscape.com)
- Control of breathing in patients with chronic obstructive lung diseases and secondary polycythemia after venesection. (medscape.com)
- Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. (medscape.com)
- Polycythemia-hyperviscosity could also be secondary to increased blood volume secondary to transfusion of blood either from maternal or sibling fetal sources. (medscape.com)
20211
- The indication was further expanded in the US in September 2021, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in people 12 years of age and older. (wikipedia.org)
Thrombocythaemia1
- Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. (medscape.com)
Diagnosis2
- Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. (medscape.com)
- Therefore, RBC mass (or Hct) is the primary determinant of neonatal blood viscosity, and up to 50% of infants with polycythemia have hyperviscosity, although only 24% of infants with hyperviscosity have a diagnosis of polycythemia. (medscape.com)
Complications2
- The resultant decreased microcirculatory perfusion and increased risk for thrombosis and ischemia of end organs are the factors responsible for most of the complications associated with polycythemia. (medscape.com)
- However, potential complications of DCC include polycythemia and hyperbilirubinemia. (medscape.com)
Chronic2
- Current major indications include Hodgkin and non-Hodgkin lymphomas, chronic lymphocytic leukemia and lymphosarcoma. (nih.gov)
- Polycythemia vera (PV) is a cancer originating from a disease-initiating stem cell in the bone marrow resulting in a chronic increase of red blood cells, white blood cells, and platelets. (qlifepro.com)
Splenectomy1
- Refractory splenomegaly may be an indication for splenectomy. (medscape.com)
Platelet count1
- In polycythaemia vera, the most common side effects include anemia (low red blood cell counts) and thrombocytopenia (low blood platelet count), bleeding, bruising, hypercholesterolaemia (high blood cholesterol levels), hypertriglyceridemia (high blood fat levels), dizziness, raised liver enzyme levels and high blood pressure. (wikipedia.org)
Molecular1
- Molecular basis for polycythemia. (medscape.com)
Clinical2
- A description of the study details for a quantitative, retrospective review of medical charts to assess the longitudinal clinical and economic burden of illness in patients with polycythemia vera (PV). (qlifepro.com)
- Most of the clinical significance of polycythemia is related to the associated increase in blood viscosity. (medscape.com)
Acute1
- Animal studies have suggested that acute fetal hypoxia can lead to increased fetal blood volume before birth, but this is unlikely to lead to significant polycythemia. (medscape.com)
Venous1
- [ 1 , 2 ] Polycythemia in the newborn is defined as a central venous Hct over 65% or a hemoglobin value above 22 g/dL. (medscape.com)
Therapeutic1
- Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area. (nihr.ac.uk)
Publication1
- Studies were included as publication up to 2017, September with English language and human subject. (ijser.org)
Search3
- We conducted a computerized Literature search involving human subjects, published in English until December 2017, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library. (ijser.org)
- We conducted a comprehensive search for articles published in English up to November, 2017. (ijser.org)
- In MEDLINE/PubMed, Cochrane Library, Embase and Web of Science databases search was performed for all studies published throughout December 2017. (ijser.org)
Blood2
- Because the increased viscosity of a fluid and a smaller radius of the conduit through which it flows can increase the internal resistance of the fluid according to Poiseuille's law, polycythemia-induced hyperviscosity increases the resistance of blood to flow, especially in the microcirculation. (medscape.com)
- Polycythemia vera is characterized by having too many red blood cells in the bloodstream. (cancerhealth.com)